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Hematopoiesis provides a suitable model for understanding adult stem cells and their niche. Hematopoietic stem cells (HSCs) 
continuously produce blood cells through orchestrated proliferation, self-renewal, and differentiation in the bone marrow (BM). 
Within the BM exists a highly organized microenvironment termed “niche” where stem cells reside and are maintained. HSC 
niche is the first evidence that a microenvironment contributes to protecting stem cell integrity and functionality in mammals. 
Although multiple models exist, recent progress has principally elucidated the cellular complexity of the HSC niche that main-
tains and regulates HSCs in BM. Here we introduce the development and summarize the achievements of HSC niche studies. 
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1  The origin of HSC niche 
The concept of “stem cell” with the properties of 
self-renewal and differentiation potential was first experi-
mentally evidenced by Till and McCulloch using in vivo 
spleen colony-forming (CFU-S) assay. Using the CFU-S 
assay, they showed that single cells could yield multiline-
ages and preserve multipotential [1,2]. Now we know that 
CFU-S assay measures mainly progenitors rather than stem 
cells, but the nature of this assay led to the niche hypothesis 
proposed by Ray Schofield in 1978. By noticing that CFU-S 
“stem cells” have less robust reconstitution capacity in irra-
diated mice compared to cells from BM, he hypothesized 
the existence of a BM niche that preserves stem cells [3]. 
Subsequent studies using in vitro methods showed that BM 
stromal cells might produce hematopoietic cytokines that 
support HSCs in culture [4,5]. However, the HSC niche 
concept was not proven in vivo until mouse genetic engi-
neering technology was developed. Two studies using 
mouse genetic models provided the first evidence of specif-
ic BM stromal cells (osteoblastic cells and bone lining cells) 
supporting mammalian HSCs in vivo [6,7]. Another subse-
quent study identified that vascular endothelial cells also 
contribute to HSC regulation in vivo [8]. Until now, despite 
significant progress achieved in identification of cellular 
and molecular constituents in HSC niche in BM, the HSC 
niche was incompletely defined and plagued by competing 
models. This can be partially explained by the heterogeneity 
of HSCs and the associated complexity of BM microenvi-
ronment. This review aims to summarize the progress of 
HSC niche studies and to examine historical consensus as 
well as controversy in the field of HSC niche studies. 
2  HSC interacting cells—a proximity principle 
Since HSC niche was originally defined as the cells that 
form a microenvironment physically holding HSCs in the 
BM, the most straightforward approach to search for HSC 
niche is to identify HSC neighboring cells in the BM. 
However, this strategy suffers from the rarity and indistin-
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guishability of HSCs in the BM. HSCs are a functionally 
defined population with the properties of long-term 
self-renewal and the ability to reconstitute all hematopoietic 
lineages. Although fluorescence activated cell sorting 
(FACS) technology allows us to identify and isolate HSCs, 
in vivo imaging HSCs is still technically challenging be-
cause the combination of multiple immunofluorescent 
markers designed for FACS assay is too complex for mi-
croscope detection [9,10]. Multiple approaches have been 
taken by different groups in attempting to locate HSCs in 
BM. HSCs are well characterized for being in the quiescent 
state which is correlated with their functionality [11–13]. 
Various methods have been used to search for quiescent 
cells in the BM, such as 5-bromodeoxyuridine (BrdU) label 
retaining, GFP-labelled histone (H2B-GFP) retention, and 
chemotherapy (e.g. 5-fluorouracil, 5FU) resistance. These 
methods are all based on the principle that quiescent cells 
are slow cycling cells that tend to retain labeled DNA and 
are resistant to DNA damage. Interestingly, the quiescent 
populations were often found close to endosteum (an inner 
bone surface) in trabecular bone, albeit by different ap-
proaches [7,14–16], suggesting that the endosteum forms a 
niche to maintain quiescent HSC subpopulations. However, 
this has been challenged by the specificity of the observed 
populations, given that some mature cells, such as memory 
lymphocytes, can also retain DNA labeling due to their long 
life span [17]. Although researchers attempted to include 
HSC positive markers in label retention studies to improve 
the accuracy of observed cells, statistical studies were tech-
nically challenging. This is because very few cells could be 
observed in sectioned BM samples and because the non-
specificity of HSC positive markers, such as Sca-1, also 
expressed in multiple types of stromal cells in BM. To 
overcome this issue, two groups independently reported that 
immunophenotypic, highly purified HSCs tended to locate 
at the endosteum in postirradiated mice, but were randomly 
distributed and unstable in non-irradiated mice [18,19]. This 
provided additional evidence for the endosteum zone serv-
ing as the HSC niche, but how this severely stressed trans-
plantation model reflects endogenous HSC distribution in 
homeostasis needs to be further explored. Other groups took 
yet another approach to locate HSCs in the BM. They sim-
plified the complicated HSC-FACS immunofluorescent 
markers into a two-color stain, thus enabling researchers to 
pinpoint endogenous HSCs under microscopy. Recently 
developed powerful imaging cytometry platform has also 
made possible comprehensive quantitative analysis of HSC 
distribution. One group used a combination of HSC positive 
marker c-kit with negative markers (CD48CD41Lineage) 
and found that the observed cells preferentially localized  
in endosteal zones where micro-vessels were also  
enriched [20]. However, this study suffered from a major 
technical challenge in that the combined markers recog-
nized more progenitor cells than HSCs, which renders the 
group’s observation rather nonspecific. Another combina-
tion, using positive marker CD150 to stain HSCs and nega-
tive markers lineage, CD41 and CD48 to exclude differenti-
ated cells, detected a more enriched HSC population in the 
two-color staining [8], although CD150 HSCs might have 
been missed with this approach [21]. In this method, HSCs 
initially were found more likely to be adjacent to sinusoid. 
Recently a comprehensive statistical HSC distribution study 
was conducted with a mathematic model to interpret HSC 
distribution. Researchers combined whole-mount confocal 
immunofluorescence imaging techniques with computation-
al modeling and found that quiescent HSCs associated spe-
cifically with small arterioles that were preferentially found 
in the endosteal region in BM. They found that ~15% HSCs 
were adjacent to arterioles and ~30% HSCs were adjacent to 
sinusoid. However, since the sinusoidal network was dense 
and almost evenly interspaced in BM, HSCs adjacent to 
sinusoids were not statistically differentiated from a random 
distribution of HSCs in BM. The physical association be-
tween HSCs (particularly quiescent HSCs) and arterioles 
was statistically significant [22]. The same statistically sig-
nificant nonrandom association was also observed in two 
recent independent studies where both groups found ~20% 
HSCs directly adjacent to megakaryocytes (MKs), a type of 
mature blood cell that produces multiple factors to regulate 
HSC quiescence [23,24]. The combination of comprehen-
sive imaging and computational modeling studies highly 
suggest the existence of independent regulatory roles from 
different niche cells that contribute to HSC maintenance and 
functional regulation in the BM.   
3  Identification of HSC regulating cells—a 
“taking one out” strategy 
The HSC niche has also been functionally defined as cells 
that prevent stem cells from depletion, thus protecting the 
host from over-exuberant stem cell proliferation [25]. The 
HSC niche is also evidenced by the initial in vivo study 
showing that the increase of trabecular bone and the associ-
ated osteoblastic cells led to the increase of HSCs [6,7]. 
This suggests that osteoblastic cells or other stromal cells 
from the endosteal region could potentially form a niche to 
support HSCs. Subsequent studies have suggested that os-
teoblasts express many factors that promote HSC mainte-
nance [26], including Stem cell factor (also known as SCF, 
KIT-ligand, KL, or steel factor), C-X-C motif chemokine  
12 (CXCL12), angiopoietin 1 and thrombopoietin  
(THPO) [14,27,28]. However, the stromal cell composition 
of the BM is as complex as its hematopoietic counterpart. 
Later studies proposed that a perivascular niche (endothelial 
cells and pericytes) might also produce those factors that 
contribute to HSC regulation. To directly study how stromal 
cells contribute to HSC regulation through those niche fac-
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tors, a “taking one out” strategy was performed to specifi-
cally delete each factor from different niche cells and study 
its influence on HSC function.  
SCF is a growth factor that binds to the c-kit receptor 
(CD 117), a receptor tyrosine kinase that expresses in HSCs 
at all stages of development [29]. SCF is non-cell autono-
mously required for HSC proliferation, survival, and func-
tion in vivo [30]. Mice that do not express SCF die in utero 
from severe anemia [30]. To investigate the functional re-
source of SCF that contributes to HSC regulation, a genetic 
approach of deleting Scf from multiple niche components 
was performed. Researchers found that HSC frequency and 
function were not affected when Scf was conditionally de-
leted from hematopoietic cells using Vav-1-Cre, from oste-
oblasts using Col2.3-Cre, and from Nestin-expressing cells 
using Nestin-Cre or Nestin-Cre/ERT2. However, HSC 
number was largely reduced from bone marrow when Scf 
was deleted from Tie-2-Cre marked endothelial cells or  
leptin receptor (Lepr)-expressing perivascular stromal  
cells [31]. This study proposed that endothelial and 
Lepr-expressing perivascular cells are a critical source of 
SCF that contributes to HSC regulation in the BM.  
The CXCL12, also known as stromal cell-derived factor 
1 (SDF-1), is a chemokine, which is an important regulator 
of leukocyte and hematopoietic precursor migration [32] 
along with G-CSF-induced HSC mobilization [33]. Deletion 
of CXCR4, a receptor for CXCL12, in HSCs severely im-
paired HSC maintenance; thus, the cells abundantly ex-
pressing CXCL12 were identified as CXCL12-abundant 
reticular (CAR) cells, a critical HSC regulating stromal cell 
in the BM. CAR cells were found surrounding sinusoidal 
endothelial cells or located near the endosteum [34]. How-
ever, the identify of CAR cells as adipo-osteogenic bipoten-
tial progenitors was not uncovered until recently [35]. A 
genetic approach to delete Cxcl12 from different niches 
revealed that both early mesenchymal progenitors and en-
dothelial cells serve as the functional CXCL12 source for 
HSC maintenance. Conditional deletion of Cxcl12 from 
hematopoietic cells or Nestin-expressing cells had little or 
no effect on HSCs or restricted progenitors. However, dele-
tion of Cxcl12 from osteoblasts depleted certain early lym-
phoid progenitors [36,37]. This suggests that CXCL12 se-
creted from distinct cellular niches in BM might have dif-
ferent functions. 
Transforming growth factor beta 1 (TGF-1) is a secret-
ed protein that performs many cellular functions, including 
the control of cell growth, cell proliferation, cell differentia-
tion, and apoptosis [38]. TGF1 signaling has been identi-
fied as a critical signaling to keep HSCs in the quiescent 
state [39]. TGF receptor (Tgfr1 or Tgfr2) deficient 
HSCs have increased proliferation but impaired long-term 
self-renewal potential [40,41]. MKs have been identified as 
the main source of supplying TGF1 in BM since deleting 
TGF1 from MKs led to HSC proliferation [24]. Nonmye-
linating Schwann cells (glial cells ensheathed autonomic 
nerves) have been identified as a critical TGF signal regu-
lator which contributes to TGF activation and HSC 
maintenance in the BM [41]. This suggests that MKs and 
neural glial cells form a distinct niche for HSC quiescence 
maintenance.  
The osteoblast niche in the endosteal region was the first 
identified HSC niche in BM, although factors from this 
niche contributing to HSC regulation have not yet been 
identified. Some researchers tended to exclude the osteo-
blast niche from the HSC functional supporting cells be-
cause deleting either Scf or Cxcl12 using Col2.3-Cre did not 
affect HSC function in mice. However, recent evidence has 
shown that Col2.3-Cre induced osteoblast oblation in mice 
impaired HSC self-renewal function, though the overall 
number of HSCs did not significantly change [42,43]. This 
suggests that Col2.3-Cre marked osteoblasts might produce 
other unknown factors that contribute to maintaining HSC 
self-renewal potential. Indeed, angiopoietin-1 [14], throm-
bopoietin [28], Jagged-1 [44], and non-canonical Wnt sig-
nals [15] from the osteoblastic niche in the endosteal region 
have been suggested for HSC regulation. However, more 
direct evidence—such as the effects of directly deleting 
those factors from the osteoblastic niche—is still needed. 
Whether the widely used Col2.3-Cre line could serve the 
purpose to study the osteoblastic niche in the endosteal re-
gion also remains questionable. For example, using current 
Cre lines, researchers still could not identify the functional 
resource of angiopoietin 1 [45], which is known to contrib-
ute to HSC regulation in vivo [14]. Furthermore, function-
ally deleting critical HSC regulation factors from the  
perivascular niche dramatically reduces HSC abundance in 
the BM; however, significant functional HSC is  
retained [31,36,37]. Although uneven recombination effi-
ciencies of Cre recombinase among cell types and trans-
genic strains explain variability in current studies, it also 
suggests that some important niche components may have 
been missed in the “taking one off” studies due to lack of 
appropriate genetic tools.  
Although competing models still exist, researchers re-
cently have formed a consensus that mesenchymal stem 
cells (MSCs) are critical for forming the HSC niche in BM. 
MSCs are self-renewing precursor cells that can differenti-
ate into bone, fat, cartilage, and stromal cells of the BM. 
The first approach using Nestin-GFP reporter mouse line 
found that Nestin+ MSCs are spatially associated with HSCs 
and highly express HSC maintenance factors, suggesting 
that MSCs and HSCs form a unique BM niche [46]. Re-
searchers subsequently used different genetic approaches 
and demonstrated how different MSCs contribute to HSC 
regulation in that Lepr+ MSCs and Prx1+ MSCs supply SCF 
and CXCL12 respectively for HSCs maintenance and that 
arteriolar Ng2+MSCs regulate HSC quiescence through un-
known mechanisms [22,37,47]. All Lepr+, Nestin+, Prx1+, 
Ng2+ cells could behave as MSCs; however, their charac-
terizations remain vague because it is still not clear at which 
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level they overlap with each other. Furthermore, it is still 
difficult to conclude whether the observed influences on 
HSCs are due to MSCs themselves or their progenies. Fu-
ture understanding of the complexity of the HSC niche will 
be achieved by targeting more specific niche cells. More 
suitable Cre lines and in-depth studies are urgently needed 
for future investigation of these HSC niches.  
4  Bone marrow niche signals during regenera-
tion 
HSCs can switch from quiescent state to proliferating state 
in order to quickly recover the hematopoiesis system injured 
from myeloablation, hemorrhage, or inflammation stress. 
Several niche signals have been suggested to be involved in 
this HSC regeneration regulation. 
Wnt signaling has been demonstrated to regulate devel-
opment of various tissues. Initial -catenin (Ctnnb1, an im-
portant component of the Wnt pathway) gain-of-function 
studies demonstrated that activating -catenin in HSCs 
promotes HSC expansion in vitro and lineage reconstitutive 
capacity in vivo, especially in cooperation with activation of 
the AKT pathway [48–50]. However, genetically deleting 
-catenin from HSCs did not affect hematopoiesis after 
transplantation [51–53]. A recent study showed that 
LT-HSCs were maintained in a quiescent state by non-
canonical Wnt signaling, via Frizzled 8 (Fzd8) receptor and 
Flamingo (Fmi, or Celsrt) during homeostasis, which an-
tagonized canonical Wnt signals. Chemotherapeutic 
stress-mediated activation of HSCs in mice resulted in re-
pressed noncanonical Wnt signaling and enhanced canoni-
cal Wnt signaling, leading to HSC activation. Loss of 
-catenin impaired HSC regeneration through enhanced 
oxidative stress [15,54,55]. All these suggest that canonical 
Wnt signaling can serve as a stress response signal to sup-
port HSC regeneration during stress. 
Fibroblast growth factor (FGF), similar to Wnt, stimu-
lates another signaling pathway that has been proven to 
promote HSC expansion in vitro [56,57]. Similarly, neither 
genetically deleting FGF receptor 1(Fgfr1) from HSCs nor 
deleting FGF2 from the niche affected HSC hematopoiesis 
after transplantation. However, when those FGF signal de-
fective mice were challenged by chemotherapeutic stress, 
their HSC regeneration and hematopoiesis recovery were 
severely impaired. This can be explained by the inactive 
FGF signals during homeostasis with low levels of FGFs in 
BM and FGFRs in HSCs; however, both FGF ligands in 
BM and FGF receptors were boosted under stress to turn on 
FGF signals for promoting HSC proliferation through acti-
vation of AKT and NF-B mechanisms. Interestingly, FGF 
signal was also shown to play a role in mobilizing HSCs to 
spleen for extramedullary hematopoiesis through regulating 
CXCR4-CXCL12 pathway that further facilitated HSC re-
generation under stress [24,58,59].  
Epidermal growth factor (EGF) signaling was also shown 
to promote HSC regeneration post injury, possibly through 
repression of the pro-apoptotic protein PUMA [60]. Dele-
tion or blockage of the adhesion molecule E-selectin was 
shown to promote HSC survival and regeneration post 
myeloablation stress through manipulating HSC and vascu-
lar niche interaction [61]. However, the effects from EGF 
and E-selectin are not limited to stressed conditions, as they 
also contribute to HSC maintenance during homeostasis.   
5  HSC maintenance in hypoxic microenviron-
ment 
An early study suggested HSCs are kept in the hypoxia mi-
croenvironment in BM [62]. Subsequent functional studies 
showed that HSCs have elevated levels of HIF-1 (hypox-
ia-inducible factors-1 alpha subunit), a cellular response 
mediator to hypoxia. The increased HIF-1 level in HSCs 
led to the up-regulation of HIF-1 targeted genes, which 
controls glycolysis. As a consequence, HSCs increased the 
rates of glycose consumption and lactate production and 
decreased the rates of oxygen consumption and mitochon-
drial potential [63]. Consistently, HIF-1 deficient  
HSCs lost their quiescence and long-term repopulation  
capacity [64]. These evidences suggest the existence of a 
hypoxia niche in BM that maintains the quiescence of 
HSCs. To search for the hypoxia zone in BM, researchers 
have directly measured the oxygen tension in the BM of live 
mice and revealed that peri-sinusoidal regions have less 
local oxygen tension and, by contrast, the endosteal region 
is less hypoxic as it is perfused with small arteries [65]. 
However, hypoxia signaling is a double-edged sword for 
HSCs. Although the elevated HIF-1 level in HSCs is crit-
ical for HSC maintenance, researchers also found that over-
stabilization of HIF-1 in HSCs by deleting Von Hip-
pel-Lindau (VHL), an E3 ubiquitin ligase for HIF-1, re-
sulted in HSC failure to move into cell cycle and loss of 
reconstitution capacity [64]. This indicated that the level of 
the HIF-1 is critical: either too high or too low will affect 
HSC function. The impact of hypoxia microenvironment on 
HSC function maintenance is still unclear. For example, 
HSCs often mobilize from BM to the peripheral blood, 
where the oxygen level is high. How HSC function is main-
tained in such a high oxygen microenvironment is not known. 
Thus, further studies are needed to understand how the func-
tional HSCs are maintained in the hypoxia niche in BM.  
6  MK niche for HSC maintenance and regen-
eration 
Recently MKs, one of the mature blood cell types, have 
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been demonstrated to constitute a critical niche for HSC 
quiescence maintenance during homeostasis and HSC re-
generation under stress. More interestingly, this MK niche 
also appears to contribute to the architectural maintenance 
of multiple stromal niches.  
Multiple BM stromal cell types have been identified as 
HSC-regulating niche cells. It remains unclear how a feed-
back from mature cells is conveyed to HSCs to adjust their 
cell cycle stage. MKs were found associated with HSCs in a 
nonrandom fashion in the BM. Functional studies show that 
MKs are able to directly regulate HSC quiescence through 
multiple HSC-regulating factors including TGF, CXCL4, 
and THPO [23,24,66,67]. More importantly, MKs can bal-
ance TGF- and FGF output, thereby regulating respective-
ly hematopoietic homeostasis and regeneration following 
chemotherapeutic stress in vivo [24,68]. This suggests that 
MKs constitute an even more specialized HSC niche, which 
can control HSC cell cycle activity based on demands, 
serving as a sensor to guide HSC switching between quies-
cence and regeneration [69]. 
Studies also suggest that MKs have vascular and osteo-
blast regulatory factors that influence the number and func-
tion of both osteoblastic and vascular niches in BM. Mature 
MKs are primarily located adjacent to blood vessels, where 
they extend transendothelial pseudopods or migrate through 
the endothelium to produce platelets [70–72]. MKs are a 
major source of both pro-angiogenetic and anti-angiogenic 
factors, which makes them a regulator for angiogenesis and 
maintenance of blood vessel integrity [73–75].  MKs have 
also been proposed as a major regulator for HSC niche re-
modeling post injury. Myelosuppression destroys the entire 
vascular niche and damages the endosteal niche [22,76,77]; 
thus, BM niche reconstitution is considered critical for HSC 
regeneration. Interestingly, MKs were found tightly associ-
ated with BM blood vessels post chemotherapeutic  
stress [24,72], contributing to blood vessel recovery through 
thrombospondin (TSP)1, an endogenous angiogenesis in-
hibitor [75]. Furthermore, post total body irradiation, sur-
viving MKs relocated to the endosteal surface of trabecular 
bone where MKs promoted osteoblast proliferation but in-
hibited osteoclast formation through producing growth fac-
tor (PDGF)- and FGF-2, which facilitates stem cell en-
graftment postirradiation [78–81].   
7  Perspective 
Recent experimentation has validated the niche concept and 
reinforced understanding of the structure of the molecular 
and cellular nature of HSC niches in BM. In the future, ma-
nipulating the stem cell niche opens the possibilities of ben-
efiting hematopoietic maintenance and regeneration. Con-
tinued progress in heightened knowledge of the key players 
of HSC niches will provide exciting new avenues for im-
proving regenerative medicine and treating hematopoietic 
disorders. This knowledge will also be applied to engineer 
ex vivo niches for HSC expansion that will facilitate stem 
cell therapy in clinics.  
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